Rxivist logo

Immunoglobulin fragment F(ab')2 against RBD potently neutralizes SARS-CoV-2 in vitro

By Xiaoyan Pan, Pengfei Zhou, Tiejiong Fan, Yan Wu, Jing Zhang, Xiaoyue Shi, Weijuan Shang, Lijuan Fang, Xiaming Jiang, Jian Shi, Yuan Sun, Shaojuan Zhao, Rui Gong, Ze Chen, Gengfu Xiao

Posted 09 Apr 2020
bioRxiv DOI: 10.1101/2020.04.07.029884 (published DOI: 10.1016/j.antiviral.2020.104868)

COVID-19 caused by the emerging human coronavirus, SARS-CoV-2, has become a global pandemic, leading a serious threat to human health. So far, there is none vaccines or specific antiviral drugs approved for that. Therapeutic antibodies for SARS-CoV-2, was obtained from hyper immune equine plasma in this study. Herein, SARS-CoV-2 RBD with gram level were obtained through Chinese hamster ovary cells high-density fermentation. The binding of RBD to SARS-CoV-2 receptor, human ACE2, was verified and the efficacy of RBD in vivo was tested on mice and then on horses. As a result, RBD triggered high-titer neutralizing antibodies in vivo, and immunoglobulin fragment F(ab')2 was prepared from horse antisera through removing Fc. Neutralization test demonstrated that RBD-specific F(ab')2 inhibited SARS-CoV-2 with EC50 at 0.07 μg/ml, showing a potent inhibitory effect on SARS-CoV-2. These results highlights as RBD-specific F(ab')2 as therapeutic candidate for SARS-CoV-2. ### Competing Interest Statement

Download data

  • Downloaded 2,201 times
  • Download rankings, all-time:
    • Site-wide: 9,105
    • In pharmacology and toxicology: 50
  • Year to date:
    • Site-wide: 77,035
  • Since beginning of last month:
    • Site-wide: 110,524

Altmetric data

Downloads over time

Distribution of downloads per paper, site-wide